venoruton forte 500 mg tablet
orifarm - hydroxyethyl-o-(bèta-)-rutoside - tablet - 500 mg - hydroxyethyl-o-(bèta-)-rutoside 500 mg - troxerutin, combinations
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lacosamide pharmascience international ltd 100 mg filmomhulde tabletten
pharmascience international limited julia house, themistokli dervi, 3 p.c. 1066 nicosia (cyprus) - lacosamide - filmomhulde tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hyprolose (e 463) ; ijzeroxide geel (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - lacosamide
lacosamide pharmascience international ltd 150 mg filmomhulde tabletten
pharmascience international limited julia house, themistokli dervi, 3 p.c. 1066 nicosia (cyprus) - lacosamide - filmomhulde tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hyprolose (e 463) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - lacosamide
lacosamide pharmascience international ltd 200 mg filmomhulde tabletten
pharmascience international limited julia house, themistokli dervi, 3 p.c. 1066 nicosia (cyprus) - lacosamide - filmomhulde tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hyprolose (e 463) ; indigokarmijn aluminiumlak (e 132) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - lacosamide
lacosamide pharmascience international ltd 50 mg filmomhulde tabletten
pharmascience international limited julia house, themistokli dervi, 3 p.c. 1066 nicosia (cyprus) - lacosamide - filmomhulde tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hyprolose (e 463) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn aluminiumlak (e 132) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - lacosamide
duloxetine boehringer ingelheim
boehringer ingelheim international gmbh - duloxetine - diabetische neuropathieën - psychoanaleptics, - behandeling van diabetische perifere neuropathische pijn bij volwassenen.
ariclaim
eli lilly nederland b.v. - duloxetine - diabetische neuropathieën - psychoanaleptics, - behandeling van diabetische perifere neuropathische pijn. ariclaim is geïndiceerd bij volwassenen.